Wall Street brokerages forecast that Iqvia Holdings Inc (NYSE:IQV) will post earnings of $1.49 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Iqvia’s earnings, with estimates ranging from $1.44 to $1.59. Iqvia posted earnings per share of $1.34 in the same quarter last year, which would suggest a positive year over year growth rate of 11.2%. The firm is scheduled to issue its next earnings results on Wednesday, May 1st.
According to Zacks, analysts expect that Iqvia will report full-year earnings of $6.25 per share for the current fiscal year, with EPS estimates ranging from $6.11 to $6.37. For the next year, analysts anticipate that the business will post earnings of $7.09 per share, with EPS estimates ranging from $6.72 to $7.37. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Iqvia.
Get Iqvia alerts:Iqvia (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 14th. The medical research company reported $1.50 EPS for the quarter, beating the consensus estimate of $1.47 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The company had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.62 billion. During the same period last year, the company earned $1.40 earnings per share. Iqvia’s quarterly revenue was up 6.6% compared to the same quarter last year.
IQV has been the topic of several research analyst reports. Goldman Sachs Group raised Iqvia from a “buy” rating to a “conviction-buy” rating in a report on Friday, January 11th. Jefferies Financial Group raised Iqvia from a “hold” rating to a “buy” rating and raised their price objective for the company from $136.00 to $150.00 in a report on Friday, January 18th. Royal Bank of Canada raised their price objective on Iqvia to $137.00 and gave the company an “outperform” rating in a report on Tuesday, October 23rd. Barclays raised their price objective on Iqvia from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, October 23rd. Finally, Piper Jaffray Companies raised their price objective on Iqvia to $131.00 and gave the company a “neutral” rating in a report on Tuesday, October 23rd. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $143.38.
Shares of IQV opened at $141.85 on Friday. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 1.41. Iqvia has a 12 month low of $91.57 and a 12 month high of $143.42. The company has a market capitalization of $28.38 billion, a price-to-earnings ratio of 32.53, a price-to-earnings-growth ratio of 1.63 and a beta of 0.88.
In other news, major shareholder Canada Pension Plan Investment sold 3,164,388 shares of Iqvia stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $123.72, for a total value of $391,498,083.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Ronald A. Rittenmeyer sold 3,840 shares of Iqvia stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $130.00, for a total value of $499,200.00. The disclosure for this sale can be found here. Insiders sold 6,751,273 shares of company stock worth $835,335,596 over the last ninety days. Corporate insiders own 6.00% of the company’s stock.
Large investors have recently modified their holdings of the company. Barings LLC boosted its stake in Iqvia by 74.1% during the third quarter. Barings LLC now owns 18,962 shares of the medical research company’s stock worth $2,460,000 after buying an additional 8,070 shares during the last quarter. State Treasurer State of Michigan boosted its stake in Iqvia by 1.0% during the third quarter. State Treasurer State of Michigan now owns 48,300 shares of the medical research company’s stock worth $6,266,000 after buying an additional 500 shares during the last quarter. BP PLC boosted its stake in Iqvia by 5.0% during the third quarter. BP PLC now owns 21,000 shares of the medical research company’s stock worth $2,725,000 after buying an additional 1,000 shares during the last quarter. DNB Asset Management AS boosted its stake in Iqvia by 0.3% during the fourth quarter. DNB Asset Management AS now owns 111,722 shares of the medical research company’s stock worth $12,979,000 after buying an additional 300 shares during the last quarter. Finally, Morgan Stanley boosted its stake in Iqvia by 14.6% during the third quarter. Morgan Stanley now owns 1,392,583 shares of the medical research company’s stock worth $180,673,000 after buying an additional 177,638 shares during the last quarter. 93.62% of the stock is currently owned by hedge funds and other institutional investors.
Iqvia Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Recommended Story: Understanding Market Liquidity
Get a free copy of the Zacks research report on Iqvia (IQV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment